Traws Pharma, Inc. Investment Income, Amortization of Discount
Traws Pharma, Inc. (TRAW) reported Investment Income, Amortization of Discount of $6.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-28.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfDiscount · last filed 2016-03-28
- Traws Pharma, Inc. investment income, amortization of discount for the quarter ending 2014-12-31 was $1.00K.
- Traws Pharma, Inc. investment income, amortization of discount for the quarter ending 2014-09-30 was $2.00K.
- Traws Pharma, Inc. investment income, amortization of discount for the quarter ending 2014-06-30 was -$2.00K.
- Traws Pharma, Inc. investment income, amortization of discount for the quarter ending 2014-03-31 was $5.00K.
- Traws Pharma, Inc. investment income, amortization of discount for fiscal 2014 was $6.00K.
| Period end | Investment Income, Amortization of Discount 3 month | Investment Income, Amortization of Discount 6 month | Investment Income, Amortization of Discount 9 month | Investment Income, Amortization of Discount 12 month |
|---|---|---|---|---|
| 2014-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28 | $3.00K derived: sum of 2 quarters · filed 2016-03-28 | $1.00K derived: sum of 3 quarters · filed 2016-03-28 | $6.00K 10-K · filed 2016-03-28 |
| 2014-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $0.00 derived: sum of 2 quarters · filed 2015-11-12 | $5.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $3.00K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $5.00K 10-Q · filed 2015-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |